GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (TSX:ASP) » Definitions » Shiller PE Ratio

Acerus Pharmaceuticals (TSX:ASP) Shiller PE Ratio : (As of Jun. 20, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Acerus Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Acerus Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Acerus Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals Shiller PE Ratio Chart

Acerus Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Acerus Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acerus Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Acerus Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acerus Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acerus Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Acerus Pharmaceuticals's Shiller PE Ratio falls into.



Acerus Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Acerus Pharmaceuticals's E10 for the quarter that ended in Sep. 2022 is calculated as:

For example, Acerus Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-0.72/120.6479*120.6479
=-0.720

Current CPI (Sep. 2022) = 120.6479.

Acerus Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201212 -13.803 95.760 -17.390
201303 -16.071 97.103 -19.968
201306 -12.585 97.182 -15.624
201309 -5.408 97.419 -6.698
201312 -12.982 96.945 -16.156
201403 -3.872 98.604 -4.738
201406 -9.439 99.473 -11.448
201409 -3.839 99.394 -4.660
201412 -8.041 98.367 -9.862
201503 -0.042 99.789 -0.051
201506 -2.155 100.500 -2.587
201509 2.312 100.421 2.778
201512 -8.928 99.947 -10.777
201603 6.916 101.054 8.257
201606 6.743 102.002 7.976
201609 -1.019 101.765 -1.208
201612 0.000 101.449 0.000
201703 -2.334 102.634 -2.744
201706 -2.318 103.029 -2.714
201709 -2.140 103.345 -2.498
201712 -2.226 103.345 -2.599
201803 -4.509 105.004 -5.181
201806 -6.864 105.557 -7.845
201809 -2.272 105.636 -2.595
201812 -4.684 105.399 -5.362
201903 -4.661 106.979 -5.257
201906 -2.316 107.690 -2.595
201909 -5.296 107.611 -5.938
201912 -0.604 107.769 -0.676
202003 -2.792 107.927 -3.121
202006 -2.362 108.401 -2.629
202009 -2.646 108.164 -2.951
202012 -2.562 108.559 -2.847
202103 -2.514 110.298 -2.750
202106 -1.124 111.720 -1.214
202109 -0.811 112.905 -0.867
202112 -0.986 113.774 -1.046
202203 -1.144 117.646 -1.173
202206 -1.319 120.806 -1.317
202209 -0.720 120.648 -0.720

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Acerus Pharmaceuticals  (TSX:ASP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Acerus Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Acerus Pharmaceuticals (TSX:ASP) Business Description

Traded in Other Exchanges
N/A
Address
7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8
Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.
Executives
Norma Beauchamp Director
Stephen Robert Gregory Director
Edward Joseph Gudaitis Director, Senior Officer

Acerus Pharmaceuticals (TSX:ASP) Headlines